Author: Editor

Habte Yimer, MD, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology Discusses Lyra Trial In Newly Diagnosed MM At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, Discusses LCAR-838M Study In Relapsed/Refractory MM At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jason Butler, PhD Associate Scientist, Regenerative Medicine and Associate Professor, Center for Discovery and Innovation, Hackensack University, Discusses Leukemia-Initiating Metabolic Switch & How Vascular Integrity Impacts It. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope Discusses Novel Induction Regimens In PTCL At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Carol Moreno, M.D., PhD Hematologist, University of Barcelona Discusses MRD As A Legitimate Surrogate Marker In CLL At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Yana Pikman, M.D. Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Childrens Hospital, Discusses LEAP Consortium In Pediatric Acute Leukemia And Their Efforts At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, M.D., PhD Group Project Leader, Oncology Development, AbbVie Discusses Venetoclax In Treatment Of MM At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nizar Bahlis, M.D. University of Calgary, Calgary Discusses ASH 2018: CASTOR & POLLUX Studies Impact At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Steven Chang, M.D., M.S. Urologic Oncologist and Health Service Researcher at Brigham and Women’s Hospital discusses Should We Be Doing Robotic Radical Nephrectomy at the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Why Not Use Bulk RNA Sequencing at the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses The Future Of Single Cell RNA Sequencing at the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Single Cell RNA Sequencing In Kidney Cancer at the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Next Step In Single Cell RNA Sequencing at the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Next Step In Single Cell RNA Sequencing at the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses How To Deal With Intra & Inter Tumor Heterogeneity at the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University of Washington Discusses Uses Of Cord Blood Transplants At The 60th ASH Annual Meeting on Dec 1, 2018.

Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University of Washington Discusses Cord Blood Transplants In Clinical Practice At The 60th ASH Annual Meeting on Dec 1, 2018.

Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University of Washington Discusses Cord Blood Matched & Mismatched Unrelated Donors At The 60th ASH Annual Meeting on Dec 1, 2018.

Victor Chow M.D. an oncologist at the University Of Washington in Seattle, Washington discusses Understanding & Using Combo Approaches With CAR T cell Therapy At The 60th ASH Annual Meeting on Dec 1, 2018.

Victor Chow M.D. an Oncologist at the University Of Washington in Seattle, Washington discusses Progressive Disease After Receiving CAR T Cell Therapy At The 60th ASH Annual Meeting on Dec 1, 2018.

Victor Chow M.D. an Oncologist at the University Of Washington in Seattle, Washington discusses Progression Of Disease & Treatment At The 60th ASH Annual Meeting on Dec 1, 2018.

Victor Chow M.D. an Oncologist at the University Of Washington in Seattle, Washington discusses Designing Prospective Trials At The 60th ASH Annual Meeting on Dec 1, 2018.

Victor Chow M.D. an oncologist at the University Of Washington in Seattle, Washington discusses Clinical Trials For The Future At The 60th ASH Annual Meeting on Dec 1, 2018.

Dr. J.J. Kiladjian ASH 2018 Headline Research Studies

Ruxopeg Phase 1-2 Trial of Ruxolitinib and Pegasys in Patients with Myelofibrosis

Real World Risk Assessment and Treatment of patients with Myelofibrosis at Community Oncology Practices in the U.S.

Koen Van Besien, M.D. Director of the Stem Cell Transplant Program, Professor of Medicine at Weill Cornell Medical College Discusses CAR T Cell Therapy Or Transplant at Lymphoma & Myeloma on October 18, 2018.

Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology & Oncology and the GW Cancer Center Discusses The Roll Of Chemotherapy In CLL at Lymphoma & Myeloma on October 18, 2018.

Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology & Oncology and the GW Cancer Center Discusses Ibrutinib Or Chemotherapy at Lymphoma & Myeloma on October 18, 2018.

Ellen Ritchie, M.D. assistant professor of medicine and a member of the Leukemia Program at the Weill Cornell Medical College Discusses Treating CML & Myelofibrosis Patients at Lymphoma & Myeloma on October 18, 2018.

Ellen Ritchie, M.D. assistant professor of medicine and a member of the Leukemia Program at the Weill Cornell Medical College Discusses Interferon As An Option at Lymphoma & Myeloma on October 18, 2018.

Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses What To Do With A Patient With Advanced CMML? at Lymphoma & Myeloma on October 18, 2018.

Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses Lenalidomide In High Risk MDS Patients at Lymphoma & Myeloma on October 18, 2018.

Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses Hypomethylating Drugs & Mutations In MDS at Lymphoma & Myeloma on October 18, 2018.

Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses How Long To Treat With Azacitidine at Lymphoma & Myeloma on October 18, 2018.

Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Whats On The Horizon For Myeloma at Lymphoma & Myeloma on October 18, 2018.

Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Triplet Drug Combo at Lymphoma & Myeloma on October 18, 2018.

Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses The Role Of Ixazomib In Front Line Therapy at Lymphoma & Myeloma on October 18, 2018.

Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Renal Insufficiency At Time Of Diagnosis at Lymphoma & Myeloma on October 18, 2018.

Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses MRD Not Ready Outside Clinicial Trials at Lymphoma & Myeloma on October 18, 2018.

Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Front Line Therapy Of Myeloma at Lymphoma & Myeloma on October 18, 2018.

Joseph Mikhael, M.D. Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen) Discusses Treating Patients Differently: High Risk Vs Standard at Lymphoma & Myeloma on October 18, 2018.

Joseph Mikhael, M.D. Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen) Discusses Next Step For Genomics In Multiple Myeloma at Lymphoma & Myeloma on October 18, 2018.

Joseph Mikhael, M.D. Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen) Discusses Genomics In Multiple Myeloma at Lymphoma & Myeloma on October 18, 2018.

C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses Should MRD Negativity Be The Goal For Every Patient at Lymphoma & Myeloma on October 18, 2018.

C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses Next Step For MRD Testing In MM at Lymphoma & Myeloma on October 18, 2018.

C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses MRD Testing: Primary Endpoint For Drug Development at Lymphoma & Myeloma on October 18, 2018.

C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses MRD Detection In MM at Lymphoma & Myeloma on October 18, 2018.

C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses How Can A Private Practice Doctor Use MRD at Lymphoma & Myeloma on October 18, 2018.

Kanti Rai, M.D. Professor of medicine at The Karches Center for Oncology Research, The Feinstein Institute for Medical Research; director of the Center for Oncology and Cell Biology, Long Island Jewish Medical Center; and professor of medicine and molecular medicine at Hofstra University Northwell School of Medicine Discusses The Changing Paradigm In The Treatment Of CLL at Lymphoma & Myeloma on October 18, 2018.

Samir Parekh, M.D. Associate Professor of medicine, hematology, medical oncology, and oncological sciences at the Icahn School of Medicine at Mount Sinai Discusses Drug Repurposing For Myeloma Patients At Lymphoma & Myeloma on October 18, 2018.

Suzanne Lentzsch, M.D., PhD Associate Professor of Medicine & Director of the Multiple Myeloma and Amyloidosis Service at Columbia University Medical Center. Discusses How To Implement MRD Testing In Daily Practice At Lymphoma & Myeloma on October 18, 2018.

Shaji Kumar, M.D. Professor of Medicine Mayo Clinic College of Medicine In Rochester, Minnesota Discusses Allogeneic Stem Cell Transplant: Multiple Myeloma At Lymphoma & Myeloma on October 18, 2018.

Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter.

Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard chemotherapy for relapsed small cell lung cancer.

Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ELIQUIS(Apixaban) In Non Cancer Setting At The 60th ASH Annual Meeting on Dec 1, 2018.

Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial: Upper Extremity & Splenic DVT At The 60th ASH Annual Meeting on Dec 1, 2018.

Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial Overall Event Rates At The 60th ASH Annual Meeting on Dec 1, 2018.

Adam Binder, M.D. Assistant Professor at Thomas Jefferson University Hospital Discusses Approving Vancomycin With Neutropenic Fever Patients At The 60th ASH Annual Meeting on Dec 1, 2018.

Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Metabolic Reprogramming At The 60th ASH Annual Meeting on Dec 1, 2018.

Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses AstraZeneca The Leader In Hematology At The 60th ASH Annual Meeting on Dec 1, 2018.

Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Monotherapy In CLL At The 60th ASH Annual Meeting on Dec 1, 2018.

Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Key Clinical Data At The 60th ASH Annual Meeting on Dec 1, 2018.

Habte Yimer, M.D. Chairman, Hematology/Oncology Department, CHRISTUS Trinity Mother Frances Hospital, Medical Oncology Specialist in Tyler, TX Discusses Where Does The Lyra Study Regiment Fit At The 60th ASH Annual Meeting on Dec 1, 2018.

Habte Yimer, M.D. Chairman, Hematology/Oncology Department, CHRISTUS Trinity Mother Frances Hospital, Medical Oncology Specialist in Tyler, TX Discusses Lyra: Front Line, First Relapse Study For MM At The 60th ASH Annual Meeting on Dec 1, 2018.

Shyamala Navada, M.D. Assistant Professor at Mount Sinai Health System Discusses Oral Rigosertib With Standard Dose Azacitidine At The 60th ASH Annual Meeting on Dec 1, 2018.

Dr. Ashutosh Tewari discusses the nature of genetic difference and aggressiveness among African-Ameican men

Dr. Nihal Mohamed discusses research on active surveillance among high risk populations, particularly African-American

Dr. Susan Slovin discusses the newly discovered Mo stage of prostate cancer

Dr. William Oh discusses the role of PARP inhibitors in treating prostate cancer

Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial Summary At The 60th ASH Annual Meeting on Dec 1, 2018.         hematologic malignancies, the mayo clinic, adam-vte trial summary, the 60th ash annual meeting, ash, adam-vte

Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University of Washington Discusses Cord Blood Transplants At The 60th ASH Annual Meeting on Dec 1, 2018.

Sarah Lee, M.D. Hematology/Oncology Fellow at Cleveland Clinic Discusses The Future Of Daratumumab At The 60th ASH Annual Meeting on Dec 1, 2018.

Sarah Lee, M.D. Hematology/Oncology Fellow at Cleveland Clinic Discusses Daratumumab In A Primary Fractory Population At The 60th ASH Annual Meeting on Dec 1, 2018.

Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France) Discusses Cellular Therapies At The 60th ASH Annual Meeting on Dec 1, 2018.

Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France) Discusses Switching From Chemotherapy to Targeted Cellular Therapies At The 60th ASH Annual Meeting on Dec 1, 2018.

Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France) Discusses Whats Next In EBV-CTLs Cellular Therapy At The 60th ASH Annual Meeting on Dec 1, 2018.

Rafael Fonseca, M.D. Clinical Investigator For The Damon Runyon Cancer Research Fund Discusses MAIA Study, AMG 420 Compound, KRD Transplant At The 60th ASH Annual Meeting on Dec 1, 2018.

Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute Discusses Daratumumab In New MM Patients, Role Of CAR-T Cells At The 60th ASH Annual Meeting on Dec 1, 2018.

Dr. William Oh discusses the potential for immunotherapy in treating prostate cancer

Amer Zeidan, MBBS Assistant Professor of Medicine (Hematology) at Yale University Discusses Transfusion Independance With Hypomethylating agents At The 60th ASH Annual Meeting on Dec 1, 2018.

Amer Zeidan, MBBS Assistant Professor of Medicine (Hematology) at Yale University Discusses Is Patient Survival Based On Physician Experience At The 60th ASH Annual Meeting on Dec 1, 2018.

Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Acalabrutinib Trial follow Up At The 60th ASH Annual Meeting on Dec 1, 2018.

Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Acalabrutinib Therapy: Infection Rate & Headaches At The 60th ASH Annual Meeting on Dec 1, 2018.

Sattva Neelapu, M.D. Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses Next Step In ZUMA Studies At The 60th ASH Annual Meeting on Dec 1, 2018.

Sattva Neelapu, M.D. Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses 2 Year Update: ZUMA-1 Study At The 60th ASH Annual Meeting on Dec 1, 2018.

Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France) Discusses Use Of EBV CTLs in Lymphoma At The 60th ASH Annual Meeting on Dec 1, 2018.

Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute Discusses Where Elotuzumab Fits In The Overall Management Strategy At The 60th ASH Annual Meeting on Dec 1, 2018.

Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute Discusses Pomalidomide, Dexamethasone, & Elotuzumab Combo Trial At The 60th ASH Annual Meeting on Dec 1, 2018.

Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute Discusses Pomalidomide, Dexamethasone, & Elotuzumab Combo Trial At The 60th ASH Annual Meeting on Dec 1, 2018.

Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Whats Next For Isatuximab At The 60th ASH Annual Meeting on Dec 1, 2018.

Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Value Of Dexamethasone At The 60th ASH Annual Meeting on Dec 1, 2018.

Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Phase 2 Study Isatuximab & Dexamethasone At The 60th ASH Annual Meeting on Dec 1, 2018.

Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses ISA Combo: Velcade, Revlimid & Dexamethasone At The 60th ASH Annual Meeting on Dec 1, 2018.

Dr. Susan Slovin discusses how the evolution of therapeutic treatment is occurring in advanced stage prostate cancer

The concept of Precision Therapy in Prostate Cancer treatment will need to rely more heavily on genetic testing

Aziz Nazha MD of Cleveland Clinic discusses using Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning at ASH 2018

Aziz Nazha MD of Cleveland Clinic discusses the overview of his study of A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes at ASH 2018. Background Allogeneic hematopoietic cell transplantation (HCT) remains the only potentially curative option for myelodysplastic syndromes (MDS). Genetic alterations have an impact on outcomes after HCT in MDS (Lindsley C, et al, NEJM 2017). Given the significant risks of transplant-related mortality and relapse, identifying patients (pts) who may or may not benefit from HCT is clinically important. We explored how the incorporation of genomic / clinical data using…

Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the next steps for Ixazomib in Multiple Myeloma after the results of the TOURMALINE-MM3 phase 3 trial. Key findings, which will be presented by Dr. Meletios Dimopoulos, include: The trial achieved its primary endpoint with NINLARO resulting in a statistically significant improvement in PFS versus placebo in adult patients diagnosed with multiple myeloma who responded to HDT and ASCT as assessed by an Independent Review Committee (IRC) (HR 0.72; 95% CI: 0.582, 0.890; p-value=0.002). This corresponds to a 28 percent reduction in risk of progression or death and a…

Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses Duration of Maintenance and the Advantage to High Risk Patients of the TOURMALINE-MM3 phase 3 study. Key findings, which will be presented by Dr. Meletios Dimopoulos, include: The trial achieved its primary endpoint with NINLARO resulting in a statistically significant improvement in PFS versus placebo in adult patients diagnosed with multiple myeloma who responded to HDT and ASCT as assessed by an Independent Review Committee (IRC) (HR 0.72; 95% CI: 0.582, 0.890; p-value=0.002). This corresponds to a 28 percent reduction in risk of progression or death and a 39…

Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the results of the phase 3 study TOURMALINE-MM3. The study is the first and only Phase 3 placebo-controlled study evaluating a proteasome inhibitor (PI) in the maintenance setting to produce data. Key findings, which will be presented by Dr. Meletios Dimopoulos, include: The trial achieved its primary endpoint with NINLARO resulting in a statistically significant improvement in PFS versus placebo in adult patients diagnosed with multiple myeloma who responded to HDT and ASCT as assessed by an Independent Review Committee (IRC) (HR 0.72; 95% CI: 0.582, 0.890; p-value=0.002). This…

Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses Risk Of Developing (t-MDS) After Chemo & Radiation At The 60th ASH Annual Meeting on Dec 1, 2018.

Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses Reasoning Behind ALL As Second Cancer Studyy At The 60th ASH Annual Meeting on Dec 1, 2018.

Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses Next Step In Research For (t-MDS) At The 60th ASH Annual Meeting on Dec 1, 2018.

Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses ALL As Second Cancer After Treatment, Explorative Study At The 60th ASH Annual Meeting on Dec 1, 2018.

Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses (t-MDS) Research & Outcomes At The 60th ASH Annual Meeting on Dec 1, 2018.

Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Ongoing Trials For CLL Patients At The 60th ASH Annual Meeting on Dec 1, 2018.

Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Advances In New Cancer Regiments At The 60th ASH Annual Meeting on Dec 1, 2018.

Peter Turecek, PhD Senior Director R&D bei Shire Discusses iPATH Study At The 60th ASH Annual Meeting on Dec 1, 2018.

Dr. Khorana M.D., Professor of Medicine, Cleveland Clinic Lerner College of Medicine, CaseWestern Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services of the Taussig Cancer Institute and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic Discusses CASSINI Trial Rivaroxaban Results At The 60th ASH Annual Meeting on Dec 1, 2018.

Dr. Khorana M.D., Professor of Medicine, Cleveland Clinic Lerner College of Medicine, CaseWestern Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services of the Taussig Cancer Institute and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic Discusses CASSINI Trial Blood Thinner Safety At The 60th ASH Annual Meeting on Dec 1, 2018.

Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Venetoclax & Carfilzomib Dose Escalation Study At The 60th ASH Annual Meeting on Dec 1, 2018.

Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Phase 3 MURANO Trial At The 60th ASH Annual Meeting on Dec 1, 2018.

Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Benefits Of Venetoclax Studies At The 60th ASH Annual Meeting on Dec 1, 2018.

Aaron Gerds, M.D., M.S. assistant professor of medicine in the Hematology and Medical Oncology department at the Cleveland Clinic Taussig Cancer Institute Discusses Azacitidine & Atezolizumab Combo Study At The 60th ASH Annual Meeting on Dec 1, 2018.

Rajat Bannerji, MD, PhD Associate Professor of Medicine Division of Hematology Oncology Robert Wood Johnson Medical School Rutgers, The State University of New Jersey Discusses Phase 1 Study Of REGN1979 At The 60th ASH Annual Meeting on Dec 1, 2018.

Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and whether this positive trial changes management in this setting.

Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic advanced NSCLC after initial systemic therapy & considers whether these results should shape clinical practice.

Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and where these results fit into management of patients in this setting.

Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what we know about results, and the implications for the current & future landscape in NSCLC.

Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office Discusses Will MRD Testing Effect Clinicians Today? at Lymphoma & Myeloma on October 18, 2018.

Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office Discusses Whats On The Horizon For MRD Testing? at Lymphoma & Myeloma on October 18, 2018.

Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office Discusses Next Step In MRD Research at Lymphoma & Myeloma on October 18, 2018.

Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office Discusses MRD Test For Myeloma & How To Use It. at Lymphoma & Myeloma on October 18, 2018.

Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office Discusses Is MRD Testing Ready For Primetime? At Lymphoma & Myeloma on October 18, 2018.

Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office Discusses Dana-Farber IFM Study Data at Lymphoma & Myeloma on October 18, 2018.

Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts discusses Whats On The Horizon For CLL at Lymphoma & Myeloma on October 18, 2018.

Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts discusses The Role Of MRD In CLL at Lymphoma & Myeloma on October 18, 2018.

Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts discusses Prophylaxis With Pi3 Kinase Inhibitors at Lymphoma & Myeloma on October 18, 2018.

Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts discusses Pi3 Kinase Inhibitors, Idelalisib, Duvelisib, & Copanlisib at Lymphoma & Myeloma on October 18, 2018.

Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts discusses Pi3 Kinase Inhibitors Autoimmune Toxicity at Lymphoma & Myeloma on October 18, 2018.

Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts discusses Duvelisib: New Treatment For Relapse Refractory CLL at Lymphoma & Myeloma on October 18, 2018.

Neil E. Kay, M.D., Professor of Medicine at the Mayo Clinic College of Medicine and a Consultant in the Department of Internal Medicine, Division of Hematology at Mayo Clinic in Rochester, Minnesota discusses How To Manage 17P Patients at Lymphoma & Myeloma on October 18, 2018

Pinkal Desai, M.D., Assistant Professor of Medicine Weill Cornell Medical College, Cornell University And Assistant Attending Physician at the New York-Presbyterian Hospital Discusses Upfront Management & Immunotherapy Of ALL At Lymphoma & Myeloma on October 18, 2018.

Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Discusses Where Is The Field Heading In CLL. At Lymphoma & Myeloma on October 18, 2018

Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Discusses New Agents In The Pipeline To Treat CLL & WM. At Lymphoma & Myeloma on October 18, 2018

Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Discusses How Therapy Changes Effect Patients With 17P Deletion. At Lymphoma & Myeloma on October 18, 2018

Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Discusses Better To Combine Ibrutinib With Rituximab? At Lymphoma & Myeloma on October 18, 2018

Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Discusses Best Drug Sequence To Treat CLL. At Lymphoma & Myeloma on October 18, 2018

Ken Anderson M.D., Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute (DFCI) Discusses RRMM, Carfilzomib, Ixazomib, MyDRUG Trial at Lymphoma & Myeloma on October 18, 2018.

Earn CME: https://naccme.com/program/7317 In this presentation from the ‘Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity and Impact of an Emerging Therapeutic Class symposium, Dr. Peter Martin provides an overview of how to approach early relapsing follicular lymphoma. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7317 In this presentation from the ‘Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity and Impact of an Emerging Therapeutic Class symposium, Dr. John P. Leonard provides an update on new data on upfront and maintenance therapy for the treatment of follicular lymphoma. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7316 In this presentation from the ‘Surviving and Thriving with B-Cell Malignancies: Surveying an Ever-Evolving Landscape symposium, Dr. Anas Younes discusses new antibodies and antibody-drug conjugates for use in the treatment of B-cell lymphoma. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7316 In this presentation from the ‘Surviving and Thriving with B-Cell Malignancies: Surveying an Ever-Evolving Landscape symposium, Dr. Nancy L. Bartlett discusses the opportunities and challenges of using kinase inhibitors in the treatment of follicular and marginal zone lymphoma. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7315 In this presentation from the ‘CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis symposium, Nurse Rita M. Jakubowski provides an overview of CAR-T in lymphoma. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7315 In this presentation from the ‘CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis symposium, Dr. Caron A. Jacobson discusses the use of auto-transplant vs. CAR-T therapy, including how to sequence and who should receive each. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7315 In this presentation from the ‘CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis symposium, Dr. Caron A. Jacobson discusses what the future of CAR-T cell therapy looks like for. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice symposium, Dr. Peter Hillmen discusses whether the sequence of novel agents for CLL matters. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice symposium, Dr. Kanti Rai provides and overview of historical changes in the CLL treatment paradigm. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice symposium, Dr. Neil E. Kay discusses treatment options for young patients with deletion 17p. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice symposium, Dr. Richard R. Furman provides an update on the use of venetoclax for CLL. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice symposium, Dr. Jennifer R. Brown provides an update on PI3K inhibitors for CLL. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice symposium, Dr. John C. Byrd provides an update on BTK inhibitors for CLL. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr. Jesús F. San Miguel discusses whether myeloma is curable. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr. Kenneth C. Anderson discusses new treatments on the horizon for patients with relapsed and refractory myeloma. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr. Cara A. Rosenbaum discusses the management of unfit and frail patients with relapsed and refractory myeloma. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr. Adriana C. Rossi discusses whether to use a three- or four-drug regimen as induction therapy for a fit patient with relapsed and refractory myeloma. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7312 In this presentation from the ‘Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment? symposium, Dr. Ajai Chari argues against using MRS as the primary goal for multiple myeloma treatment. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7312 In this presentation from the ‘Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment? symposium, Dr. C. Ola Landgren argues that MRS is new primary goal for multiple myeloma treatment. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging Clinical Data and Implications on Current Practice symposium, Dr. Koen van Besien discusses whether acute myeloid leuekemia patients between the ages of 60 and 80 should receive an allogeneic stem cell transplant. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging Clinical Data and Implications on Current Practice symposium, Dr. Gail J. Roboz discusses minimal residual disease in acute myeloid leukemia (AML). © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in AML: Evaluating Emerging Clinical Data and Implications on Current Practice symposium, Dr. Sanmin Lee breaks down the 500-gene mutation report for patients with acute myeloid leukemia (AML). © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in AML: Evaluating Emerging Clinical Data and Implications on Current Practice symposium, Dr. Gail J. Roboz discusses the correct targets for patients with newly diagnosed acute myeloid leukemia (AML). © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium, Dr. Koen van Besien discusses which patients with acute lymphocytic leukemia should receive a stem cell transplant. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium, Dr. Pinkal Desai discusses the use of immotherapy for acute lymphocytic leukemia (ALL). © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium, Dr. Pinkal Desai outlines the diagnosis and treatament of newly diagnosed acute lymphocytic leukemia (ALL). © 2018 Imedex, an HMP Company

Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population.

Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line therapy for advanced NSCLC, with helpful new info on those completing 2 years of pembro & implications for practice.

In this weeks video, Dr. Brian G.M. Durie talks about ways myeloma patients, caregivers, or family members can give back to the myeloma community. The BOTTOM LINE: The Myeloma Warrior Spirit means having the energy and resilience to seek out the best care for patients.

In this weeks video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients. BOTTOM LINE: The FDA approval of once-weekly dosing of Kyprolis is effective, more convenient for patients, and doesnt lead to additional toxicities.

In this weeks video, Dr. Brian G.M. Durie discusses the Black Swan Research Initiatives 3 Cure trials, which use new treatment protocols. The BOTTOM LINE: Using new treatment protocols with MRD-negativity and negative PET/CT scans as endpoints, there is a strong possibility that we will identify patients as cured.

In this weeks video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in combination with dexamethasone to treat multiple myeloma patients who are refractory to IMiDs, proteasome inhibitors, and daratumumab. BOTTOM LINE: Selinexor will likely be approved by the FDA, demonstrating its safety and efficacy in combination with other myeloma therapies.

In this weeks video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma next-generation sequencing (NGS) and next-generation flow (NGF). The BOTTOM LINE: The FDA approval of the NGS test for MRD is excellent news, but this testing is still not ready for use in day-to-day clinical practice.

In this weeks video, Dr. Brian G.M. Durie comments on why it is not necessary for multiple myeloma patients to have their DNA sequenced. BOTTOM LINE: For myeloma patients, DNA sequencing is helpful in research trials, but it is not necessary for the day-to-day management of the disease.

In this video, Dr. Brian G.M. Durie explains how researchers are studying minimal residual disease (MRD) testing further to better understand sustained MRD-negativity. The BOTTOM LINE: MRD-negative status is great for a myeloma patient to have, but it still does not mean the patient is cured.

In this video, Dr. Brian G.M. Durie explains that active myeloma is diagnosed if a patient has CRAB features and myeloma-defining events. He also sheds light on a new set of criteria for high-risk smoldering multiple myeloma, known as the 2/20/20 rule. BOTTOM LINE: Talk with your doctor to assess if you have high-risk smoldering multiple myeloma.

Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Xofigo Program. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Stivarga Program. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Regorafenib Program. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Copanlisib Program. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

CRISTIANE DECAT BERGEROT, PhD PSYCHOLOGIST, POSTDOCTORAL FELLOW CITY OF HOPE COMPREHENSIVE CANCER CENTER discusses THE IMPACT OF THE PSYCHOSOCIAL MILIEU ON QUALITY OF LIFE AND SURVIVAL At the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Eric A. Singer, MD, MA, MS, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Section of Urologic Oncology Rutgers Cancer Institute of New Jersey Director, Distinction in Bioethics Program Rutgers Robert Wood Johnson Medical School discusses Ethical Issues in Kidney Cancer ?Research and Treatment at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Bellinda King-Kallimanis, PhD of U.S. Food and Drug Administration, Maryland (FDA ) discusses Incorporating Relevant and Meaningful ?Patient-Reported Outcomes in ?RCC Clinical Trials? at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department – Hospital São Lucas da PUCRS/ Oncoclínicas Porto Alegre Visiting Scientist at Dana-Farber Cancer Institute/ Harvard Medical School discusses Patient And Physician Perspective at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Samra Turajlic BA, MBBS, MRCP, PhD, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust, London Cancer Research UK Clinician Scientist, Francis Crick Institute, London discusses Tracking Renal Cancer Evolution Through Space And Time at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

E. Jason Abel MD, FACS University of Wisconsin discusses Cytoreductive nephrectomy Placing recent clinical trials in context at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL

Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage III NSCLC and highlights new data on overall survival and the different results in patient subgroups.

Earn CME: https://naccme.com/program/7309 In this Key Insights activity, Drs. Morton Coleman and John P. Leonard discuss highlights in lymphoma from Lymphoma & Myeloma 2018: An International Congress on Hematologic Malignancies. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7308 In this Key Insights activity, Drs. Morton Coleman and Richard R. Furman discuss CLL-related highlights from Lymphoma & Myeloma 2018: An International Congress on Hematologic Malignancies. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7307 In this Key Insights activity, Drs. Morton Coleman and Ruben Niesvizky discuss myeloma presentation highlights from Lymphoma & Myeloma 2018: An International Congress on Hematologic Malignancies. © 2018 Imedex, an HMP Company

Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Drs. Langer, Aggarwal, Bazhenova, and Ross examine a series of NSCLC cases. © 2018 Imedex, an HMP Company

Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Lyudmila Bazhenova discusses EGFR resistance in the era of osimertinib. © 2018 Imedex, an HMP Company

Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses frontline options for targeted therapy with EGFR TKIs. © 2018 Imedex, an HMP Company

Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Helen Ross discusses the heterogeneity of NSCLC and precipitating oncogenic driver mutations. © 2018 Imedex, an HMP Company

Michael A.S. Jewett DEPARTMENT OF SURGICAL ONCOLOGY PRINCESS MARGARET CANCER CENTRE DIVISION OF UROLOGY THE UNIVERSITY OF TORONTO discusses Heterogeneity of Renal Cell Carcinoma: Lessons learned from biopsy and active surveillance of small renal masses (SRM) at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Kimberly Allman, MSN, CNP Cleveland Clinic Taussig Cancer Institute discusses Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic Renal Cell Carcinoma at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Ritesh Kotecha discusses Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Neeraj Agarwal Huntsman Cancer Center discusses Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab:?Results of the dose-escalation stage in ?patients with treatment-naïve advanced ?renal cell carcinoma at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Andrey Soares Medical Oncologist Centro Paulista de Oncologia and Hospital Israelita Albert Einstein SPChair LACOG GU gives an UPDATES LATIN AMERICAN COOPERATIVE ONCOLOGY GROUP (LACOG) at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Rodolfo Borges dos Reis, MD, PhD Uro-oncology Ribeirao Preto Medical School discusses LARCG Latin American Renal Cancer Group at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Alberto Diaz de Leon M.D. discusses Whole Body MRI for Detection of Renal Cell Carcinoma Osseous Metastases at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Abhishek A. Chakraborty Instructor in Medicine Department of Medical Oncology Laboratory of William Kaelin Dana-Farber Cancer Institute Harvard Medical School discusses Targeting Vulnerabilities Arising from Dysregulated Histone Demethylase Function in Kidney Cancer at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess Medical Center Research Fellow, Dana Farber Cancer Institute discusses A Secreted PD-L1 Splice Variant that Covalently Dimerizes and Mediates Immunosuppression at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

A Ari Hakimi MD Assistant Member, Department of Surgery, Urology Service Member, Immunogenomics and Precision Oncology Platform discusses the Novel metabolic insights into RCC biology and immune response at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Toni K. Choueiri, MD Director, Lank Center for Genitourinary Oncology Department of Medical Oncology Dana-Farber Cancer Institute discusses Neovax: From Translation to Bedside From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Thai H. Ho, MD, PhD Mayo Clinic Arizona discusses Targeting Epigenetics and Chromatin Remodeling Genes From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Thomas Powles Director of Barts Cancer Centre discusses The next therapeutic targets: TGFbeta From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Abhishek Tripathi MD Assistant Professor of Medicine University of Oklahoma Stephenson Cancer Center discusses Adenosine Pathway Inhibitors From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Ranjit S. Bindra, M.D., Ph.D. Associate Professor Departments of Therapeutic Radiology and Experimental Pathology Yale Cancer Center discusses Exploiting oncometabolite-induced DNA repair defects From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses whether the results improve outcomes enough to change our standard of care in this setting.         IMpower133, atezolizumab,  first line chemo, extensive stage SCLC

Suzanne Cole, MD FACP Medical Director, Community Cancer Clinic Richardson Plano UT Southwestern Medical Center discusses Engaging Clinical Trialists in the Community Setting From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Robert G. Uzzo, M.D. Willing G. Pepper Chairman of Surgery Fox Chase Cancer Center Temple University School of Medicine Chair, Department of Urology Urological Institute at Einstein Healthcare Network Philadelphia, PA USA discusses Creating Synergy in RCC: Collaborative Approaches to Value From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Hyung L. Kim, M.D. Director, Academic Urology Programs Cedars Sinai Medical Center discusses What is the Next Cytoreductive Surgical Trial? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology MD Anderson Cancer Center discusses Combination Checkpoint Blockade with Surgery From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Phillip M. Pierorazio, MD Associate Professor of Urology and Oncology Brady Urological Institute, Department of Urology? Johns Hopkins Medicine, Baltimore, Maryland discusses Neoadjuvant PD1 Blockade to Prime the Immune System From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Dr. Andrew W. Silagy Urologic Oncology Research Fellow Memorial Sloan Kettering Cancer Center discusses An Evaluation of the Role of Cytoreductive Nephrectomy in Patients with Sarcomatoid RCC From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Nizar M. Tannir University of Texas MD Anderson Cancer Center, Houston, TX, USA discusses CheckMate 214 Retrospective Analyses From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Nieves Martinez Chanza Department of Oncology, Jules-Bordet Institute, Free University of Brussels (Belgium) discusses Safety and efficacy of checkpoint inhibitors From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Tian Zhang, MD Assistant Professor of Medicine Duke Cancer Institute discusses PDIGREE From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Thomas Powles Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, UK discusses Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Rana R. McKay, MD Assistant Professor of Medicine UC San Diego discusses Rationally Targeting the Bone with Radium Plus Cabozantinib From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Matt Campbell MD Assistant Professor GU Medical Oncology UT MD Anderson Cancer Center discusses Ongoing Clinical Trial Update: A Pilot Study of Pre-surgical Tremelimumab with or without Tissue Cryoablation From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Moshe C. Ornstein MD MA, Laura S. Wood RN MSN OCN, Kimberly Allman MSN CNP, Allison Martin PA-C Timothy Gilligan MD, Jorge A. Garcia MD, Brian I. Rini MD Cleveland Clinic Taussig Cancer Institute discusses Phase II trial of intermittent nivolumab From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Hans Hammers MD, PhD Associate Professor of Internal Medicine in the Division of Hematology-Oncology at UT Southwestern Medical Center discusses Tayloring Therapy: Therapy Intensification and Discontinuation From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Charles G. Drake MD / PhD Director GU Medical Oncology Co-Director: Immunotherapy Program Associate Director for Clinical Research Professor of Oncology and Urology Herbert Irving Cancer Center at Columbia University discusses Beyond Checkpoint ?Blockade From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Primo N Lara, Jr., MD Director, University of California Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean for Cancer Programs UC Davis School of Medicine, Sacramento, CA discusses Metastatic Renal Cell Cancer: Who Deserves Monotherapy? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Michael B. Atkins, M.D. William M. Scholl Professor and Vice Chair Department of Oncology Deputy Director Georgetown-Lombardi Comprehensive Cancer Center discusses RCC: Putting Frontline Combination Data into Perspective From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Ewelina Morawa, MD Executive Medical Director CRISPR Therapeutics discusses Allogeneic Anti-CD70 CAR T Cells ?for Renal Cell Carcinoma From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Steven L. Chang, MD, MS Assistant Professor of Surgery, Harvard Medical School Surgical Oncologist, Dana-Farber Cancer Institute Associate Surgeon, Division of Urology, Brigham and Womens Hospital discusses Laparoscopic Vs Robotic Radical Nephrectomy: What are the Costs and Benefits? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Enucleation of Renal Mass: Why Would You Not Keep Your Distance? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Gopal N. Gupta, MD, FACS Associate Professor Departments of Urology, Surgery and Radiology Cardinal Bernardin Cancer Center Loyola University Health System discusses Pro vs Con for Enucleation From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Steven S. Raman, MD FSAR FSIR Professor of Radiology, Urology and Surgery Division of Abdominal Imaging & Intervention Departments of Radiology and Urology David Geffen School of Medicine at UCLA discusses The Radiological Biopsy: Are we there yet? Imaging based renal mass diagnosis. From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

John Leppert, MD MS Associate Professor Stanford University Director of Urologic Oncology, VA Palo Alto discusses Overdiagnosis and the Harms of Overtreatment of Renal Cell Carcinoma From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Timothy McClure, MD Assistant Professor of Urology Assistant Professor of Interventional Radiology Weill Cornell Medicine discusses Emerging Ablative Technologies – Whats New And Is It Better? from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Jaime Landman Professor of Urology and Radiology Chairman, Department of Urology UCI discusses Renal mass biopsy in 2018: When, where and how? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

David Braun, MD, PhD, Dana-Farber Cancer Institute discusses Single Cell RNA-Sequencing in RCC from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Dr. Lisa Derosa, MD PhD Candidate Immunoncology – Pr. L. Zitvogel discusses The impact of the stool microbiome in RCC from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, UT Southwestern Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair in Cancer Research Professor of Internal Medicine/Hematology-Oncology Cancer Biology, Genetics, Development and Disease University of Texas Southwestern Medical Center discusses An Empirical Approach to Dissect the TME in RCC from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

James J. Hsieh MD PhD Professor, Molecular Oncology, Siteman Cancer Center, Washington University in St. Louis discusses RCC Profiling from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Neeraj Agarwal, MD Professor of Medicine Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research Co-Leader, HCI Experimental Therapeutics Program (CCSG Program) Director, GU Medical Oncology Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Discusses Cell-free DNA (cfDNA) from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University discusses Cost-Effective Biomarkers Ready at our fingertips? from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Larotrectinib Program. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Do-Youn Oh, M.D., of Seoul National University Hospital discusses Treating Advanced Biliary Cancer: M7824 Data. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Do-Youn Oh, M.D., of Seoul National University Hospital discusses Pembrolizumab Monotherapy In Biliary Cancer. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Do-Youn Oh, M.D., of Seoul National University Hospital discusses Future Of Biliary Cancer Treatment. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Do-Youn Oh, M.D., of Seoul National University Hospital discusses Future Of Biliary Cancer Treatment. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Sanjay Popat, M.D., of The Royal Marsden Hospital Discusses ALTA-1L Trial CNS Efficacy. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Tagawa, M.D., of Weill Cornell Medicine discusses PSMA-617 Study. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Tagawa, M.D., Of Weill Cornell Medicine discusses Availability Of PSMA-617 Radionuclide Therapy. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Whats on The Horizon For Bayer Pharmaceuticals. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.